Dougall H T, McLay J
Department of Medicine and Therapeutics, University of Aberdeen Medical School, Scotland.
Drug Saf. 1996 Aug;15(2):91-106. doi: 10.2165/00002018-199615020-00002.
A large number of drugs within the 3 currently classes of calcium antagonists are in common medical use for the treatment of hypertension and ischaemic heart disease. The reported adverse effect profile for each of these drugs varies, but tends to hold true to drug class and are typified by the adverse reactions reported for nifedipine and amlodipine (dihydropyridines), diltiazem (benzothiazepines) and verapamil (phenylalkylamines). Minor adverse effects such as flushing, headache, ankle oedema, palpitations and constipation are not uncommon and frequently require the cessation of treatment. Of greater concern affecting the wide and common first-line use of calcium antagonists is the as-yet unresolved issue of a reportedly greater risk of myocardial infarction and death following the use of short-acting nifedipine in patients with a history of hypertension, myocardial infarction or angina. Until this issue is fully resolved, it would seem prudent to limit the use of this agent in 'at-risk' patients and to await the results of further prospective studies before a final conclusion can be made.
目前3类钙拮抗剂中的大量药物常用于治疗高血压和缺血性心脏病。据报道,这些药物各自的不良反应情况有所不同,但往往与药物类别相符,以硝苯地平和氨氯地平(二氢吡啶类)、地尔硫䓬(苯并硫氮䓬类)和维拉帕米(苯烷基胺类)所报道的不良反应为典型。诸如面部潮红、头痛、脚踝水肿、心悸和便秘等轻微不良反应并不罕见,且常常需要停药。影响钙拮抗剂广泛且普遍作为一线用药的更令人担忧的问题是,据报道,有高血压、心肌梗死或心绞痛病史的患者使用短效硝苯地平后,心肌梗死和死亡风险更高,而这一问题尚未得到解决。在这个问题完全解决之前,在“高危”患者中限制使用这种药物,并等待进一步前瞻性研究的结果再得出最终结论,似乎是谨慎之举。